Program
durvalumab
Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.
Drug pageDurvalumab: every studyMany companies study it; this page follows only the 100 they lead. All 482 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 8643 open or running | phase 4since May 27, 2020 | Sep 14, 2012 | Nov 30, 2026phase 2 · NCT07081633 |
| Bristol-Myers Squibb | 70 open or running | phase 2since Feb 16, 2016 | Nov 25, 2015 | none ahead |
| AbbVieits history only | 20 open or running | phase 2since Feb 27, 2015 | Feb 27, 2015 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Advaxisits history only | 10 open or running | phase 2since Nov 6, 2014 | Nov 6, 2014 | none ahead |
| AGO Researchits history only | 11 open or running | phase 2since Nov 11, 2020 | Nov 11, 2020 | Jan 2028phase 2 · NCT04644289 |
| Boston Scientificits history only | 11 open or running | phase 2since Sep 1, 2021 | Sep 1, 2021 | Jun 2027phase 2 · NCT05063565 |
| Eli Lillyits history only | 10 open or running | phase 1since Oct 7, 2015 | Oct 7, 2015 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Biocompatibles UK, Daiichi Sankyo, Parexel, Apices Soluciones S.L., IQVIA Pty, Myriad Genetic Laboratories, PRA Health Sciences and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2015First study: phase 1 study in Multiple MyelomaFirst studyNCT02616640 · 114 enrolled · United States, Canada, France and more
- Feb 16, 2016Phase 2 study in Multiple MyelomaNCT02685826 · 56 enrolled · United States, Canada, Denmark and more
- Apr 5, 2016Phase 2 study in LymphomaNCT02733042 · 106 enrolled · United States, France, Germany and more
- May 16, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02775903 · 213 enrolled · United States, Austria, Belgium and more
- Jun 17, 2016Phase 2 study in Multiple MyelomaNCT02807454 · 37 enrolled · United States, Belgium, Canada and more
- Dec 19, 20162 phase 2 studiesNCT03000452, NCT03003520
TargetBeta
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 7 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more | 2 | Completed | Apr 24, 2022 | 46 |
| NCT03000452Multiple Myeloma · United States, Austria, Greece and more | 2 | Completed | Sep 18, 2017 | 18 |
| NCT02807454Multiple Myeloma · United States, Belgium, Canada and more | 2 | Terminated | Jan 3, 2022 | 37 |
| NCT02775903Leukemia, Myeloid, Acute · United States, Austria, Belgium and more | 2 | Completed | Dec 31, 2018 | 213 |
| NCT02733042Lymphoma · United States, France, Germany and more | 2 | Completed | Mar 6, 2019 | 106 |
| NCT02685826Multiple Myeloma · United States, Canada, Denmark and more | 2 | Completed | Dec 15, 2017 | 56 |
| NCT02616640Multiple Myeloma · United States, Canada, France and more | 1 | Completed | Nov 23, 2018 | 114 |
How it is read
Names in the registry
- “Durvalumab”, 55 entries
- “MEDI4736”, 20 entries
- “durvalumab”, 7 entries
- “MEDI4736 (Durvalumab)”, 3 entries
- “MEDI4736 + tremelimumab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 30 studies
- Small Cell Lung Carcinoma, 9 studies
- Carcinoma, Hepatocellular, 8 studies
- Urinary Bladder Neoplasms, 5 studies
- Squamous Cell Carcinoma of Head and Neck, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.